Enginprime Medical, a Shanghai and Hangzhou-based developer of percutaneous ventricular assist device (pVAD) technology, announced on August 17 that it has closed a $12 million Series A financing round exclusively led by Qiming Venture Partners, a large, established venture capital firm. Proceeds will fund a registration clinical trial of Enginprime’s lead device, OpusOne, in China, along with regulatory submissions and early-stage clinical development elsewhere. Enginprime is privately held and does not trade under a stock ticker, so this is a venture-financing story rather than a public-markets event, but it is a useful signal of institutional investor interest in a device category dominated globally by a single company.
What a pVAD Does
A percutaneous ventricular assist device is a temporary mechanical pump inserted through a blood vessel, using a catheter, to help the heart pump blood during high-risk procedures or episodes of severe heart failure, without the open-heart surgery a permanently implanted heart pump would require. Because the device is inserted through a vessel rather than surgically implanted, the diameter of the catheter carrying it matters a great deal: a narrower catheter generally means an easier, lower-risk insertion, while still needing to move enough blood to meaningfully support a failing heart. Enginprime says OpusOne is designed to deliver higher blood flow from a smaller catheter profile than existing devices, using what the company’s lead investor describes as a foldable impeller design, meaning the pump’s internal blades collapse for insertion and expand once in place. That description of the device’s advantages comes from Qiming Venture Partners rather than from published clinical data, and no efficacy or safety results are presented in this release.
Where Enginprime Came From
Enginprime was founded in 2023 by Voyagers Capital, a healthcare-focused venture fund that builds companies internally alongside outside entrepreneurs, a model sometimes called venture creation, rather than only investing in already-formed startups, together with a team of engineers. The company previously announced a first-in-human study of OpusOne, though this release does not restate the results of that study, and none are assumed here; the current financing is aimed at moving the device into a formal registration trial in China, the type of larger, regulator-mandated study that Chinese authorities require as evidence before approving a device for the domestic market, a distinctly later stage than an initial feasibility study.
The Lead Investor
Qiming Venture Partners, the round’s sole lead investor, describes itself as a firm founded in 2006 that manages eleven U.S. dollar funds and seven RMB funds, with $9.5 billion in total capital raised, investing in technology and healthcare companies at early and growth stages. The firm says it has backed more than 580 companies since its founding, with over 210 of those achieving exits through IPOs on exchanges including the NYSE, Nasdaq, Hong Kong Stock Exchange, and the Shanghai and Shenzhen exchanges, or through acquisitions, and that more than 80 of its portfolio companies have reached unicorn or larger valuations. Those figures describe the firm’s overall track record rather than anything specific to Enginprime, and are Qiming’s own reporting rather than independently audited numbers.
What the Companies Are Saying
Qiming’s Shuo Mao, who led the deal, said the foldable impeller design achieves greater blood flow with a lower catheter profile, which the firm believes could reduce clinical complications and broaden the range of patients eligible for the therapy compared with existing options; Mao also said no comparable product has yet secured global regulatory approval. Those are the investor’s characterizations of the device’s potential rather than confirmed clinical findings, and should be read as an investment thesis rather than an established medical fact. Enginprime CEO Zhiyong Liu and Voyagers Capital partner Fiona Zhang both framed the funding as validation of the company’s engineering progress and a step toward bringing OpusOne to the Chinese and global markets.
The Market Enginprime Is Entering
The pVAD category Enginprime is entering already has an established, dominant commercial leader: Abiomed’s Impella platform, which Johnson & Johnson acquired in a deal completed in December 2022 for an enterprise value of approximately $16.6 billion, at the time the largest medtech acquisition of that year. That acquisition illustrates both the commercial scale available to a successful pVAD company and the size of the incumbent Enginprime and other newer entrants would need to compete against in order to gain meaningful market share. The release does not compare OpusOne to Impella directly, and no head-to-head data between the two devices is available; a foldable-impeller design intended to reduce catheter size is, at least conceptually, aimed at a real limitation of current pVAD technology, since larger catheter profiles are associated with more vascular access complications, but whether Enginprime’s specific approach delivers on that goal in practice remains to be shown in its own clinical trials.
What’s Next
No valuation for Enginprime, ownership stake acquired by Qiming, or specific timeline for when the China registration trial will begin enrolling was disclosed in this release, and none are estimated here. This article covers a private venture capital financing and is not an investment recommendation.
Sources
Enginprime Medical Closes $12M Series A Financing, PRNewswire, August 17, 2026.
Johnson & Johnson Completes Acquisition of Abiomed, December 22, 2022, cited for background on the pVAD market’s dominant incumbent.
Editorial Disclosure
This article is based on a press release issued by Enginprime Medical Inc and Voyagers Capital on August 17, 2026, distributed via PRNewswire, with market background on the Johnson & Johnson-Abiomed acquisition drawn from Johnson & Johnson’s own announcement, cited above. Enginprime Medical is a privately held company and does not trade under a stock ticker; no securities are discussed in this article. BioTech Stocks Daily was not compensated for this coverage. Statements regarding the device’s clinical advantages, market opportunity, or future regulatory outcomes are characterizations from the company and its investors rather than independently verified findings. This article is for informational and educational purposes only, does not constitute investment advice, and is not medical advice. See our full DISCLAIMER.
